VYNE Therapeutics Inc.VYNENASDAQ
Loading
Net Income Growth AcceleratingAccelerating
Percentile Rank84
5Y CAGR+40.2%
Year-over-Year Change
Year-over-year net income growth rate
5Y CAGR
+40.2%/yr
Long-term compound
Percentile
P84
Within normal range
vs 5Y Ago
5.4x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 33.56% |
| Q3 2025 | -26.50% |
| Q2 2025 | 33.17% |
| Q1 2025 | 28.37% |
| Q4 2024 | 1.11% |
| Q3 2024 | -29.25% |
| Q2 2024 | -50.52% |
| Q1 2024 | -0.99% |
| Q4 2023 | 6.01% |
| Q3 2023 | 34.54% |
| Q2 2023 | -78.90% |
| Q1 2023 | 43.47% |
| Q4 2022 | -5.14% |
| Q3 2022 | -11.60% |
| Q2 2022 | -281.50% |
| Q1 2022 | 140.36% |
| Q4 2021 | 45.64% |
| Q3 2021 | -6.83% |
| Q2 2021 | 3.05% |
| Q1 2021 | 11.35% |
| Q4 2020 | 6.20% |
| Q3 2020 | 85.24% |
| Q2 2020 | -316.18% |
| Q1 2020 | -87.15% |
| Q4 2019 | -27.55% |
| Q3 2019 | -2.29% |
| Q2 2019 | 12.70% |
| Q1 2019 | -7.27% |
| Q4 2018 | -36.95% |
| Q3 2018 | -53.91% |
| Q2 2018 | 34.05% |
| Q1 2018 | -36.43% |
| Q4 2017 | -13.52% |
| Q3 2017 | -32.81% |
| Q2 2017 | -12.40% |
| Q1 2017 | -13.17% |
| Q4 2016 | -42.35% |
| Q3 2016 | 0.00% |